Lexaria Bioscience Corp (LEXX)

Lexaria Bioscience Corp. is a biotechnology company listed on NASDAQ under the ticker LEXX. The company develops DehydraTECH, a patented drug delivery platform designed to combine active pharmaceutical ingredients with specific long-chain fatty acid-rich triglyceride oils and carrier compounds. According to the company, this approach is intended to improve absorption into the bloodstream, support lower dosing, and enhance tolerability while enabling oral ingestion methods.

DehydraTECH has been applied to a range of molecules, including GLP-1 and GIP drugs, vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, nicotine and related analogs, and cannabinoids. The technology is also used across multiple therapeutic areas, such as diabetes, weight loss, hypertension, epilepsy, and heart disease, and can be incorporated into formats including oral suspensions, tablets, capsules, foods, beverages, and other oral or topical products. Founded in 2004 and headquartered in Kelowna, Canada, the company was previously known as Lexaria Corp. before adopting its current name in 2016.

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.